{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:12:11Z","timestamp":1790691131201,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The World Health Organization (WHO) has proposed a plan for the elimination of viral hepatitis with a goal of reducing new hepatitis infections by 30% and 90% in 2020 and 2030, and associated mortality by 10% and 65% respectively. Actions and targets to reach these goals include improving hepatitis B virus (HBV) vaccination programs, the prevention of mother\u2010to\u2010child transmission of HBV, improving the safety of blood products and injections, risk reduction policies and optimizing the diagnosis and treatment of hepatitis. The goal of eliminating hepatitis C virus (HCV) by 2030 is based on three main actions: increased screening, strengthening access to care and the prevention of infections and re\u2010infections. But, can this goal be reached? The answer to this question is yes in some countries, perhaps in others and no in most countries. Success will be limited by a \u201cdiagnosis burn\u2010out\u201d with 5 times more new viral infections than diagnoses in 2016 and a \u201ctreatment burn\u2010out\u201d with cure rates that are 5 times lower than the number of new infections. Nevertheless, France, like 10 other countries, is on track to achieve the WHO elimination plan by 2030. In France, the prioritization of oral antivirals in 2013\u20102014 which was extended to high\u2010risk populations in 2015 (HIV\u2010infected patients) and 2016 (men who have sex with men, dialyzed or kidney transplant recipients), then in 2017 to universal treatment with full coverage by French national healthcare (10 to 15\u00a0000 treatments per year) has resulted in half of the 120\u00a0000 patients needed to be treated by 2022 have been treated. Renewed efforts should make it possible to reach the target announced by the French Minister of Health in May 2018 by 2025.<\/jats:p>","DOI":"10.1111\/liv.14862","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T05:38:49Z","timestamp":1624340329000},"page":"45-49","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Is elimination of HCV realistic by 2030: France"],"prefix":"10.1111","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9772-9591","authenticated-orcid":false,"given":"Stanislas","family":"Pol","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Centre D\u00e9partement d\u2019H\u00e9patologie H\u00f4pital Cochin APHP; INSERM U1223 Institut Pasteur Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loriane","family":"Lair\u2010Mehiri","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Centre D\u00e9partement d\u2019H\u00e9patologie H\u00f4pital Cochin APHP; INSERM U1223 Institut Pasteur Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Vallet\u2010Pichard","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Centre D\u00e9partement d\u2019H\u00e9patologie H\u00f4pital Cochin APHP; INSERM U1223 Institut Pasteur Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30579-7"},{"key":"e_1_2_9_3_1","unstructured":"WHO.Global health sector strategy on viral hepatitis 2016\u20102021. WHO.http:\/\/www.who.int\/hepatitis\/strategy2016\u20102021\/ghss\u2010hep\/en\/. Accessed September 23 2020"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.08.035"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis385"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32111-1"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30329-0"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250630"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21734"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4493-2"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1007"},{"key":"e_1_2_9_13_1","volume-title":"11th European Congress on heroin addiction and related clinical problems","author":"Remy AJ","year":"2014"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2889-4"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12740"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14324"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9100130"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.065"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14862","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.14862","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T08:32:00Z","timestamp":1693297920000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.14862"}},"subtitle":[],"editor":[{"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":17,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/liv.14862"],"URL":"https:\/\/doi.org\/10.1111\/liv.14862","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"2021-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}